10.19.10
U.K.-based Provexis plc has raised funds to allow the company to accelerate its strategy of developing new functional and medical food ingredients and technologies. The company is actively looking to acquire new technologies while continuing to screen a range of possible opportunities.
The recruitment of three R&D and formulation scientists adds further depth and knowledge to the experienced management and scientific teams based at the University of Liverpool and the University of Aberdeen’s Rowett Institute of Nutrition and Health.
The technology pipeline continues to strengthen with the extension of the Crohn’s disease trial into two new centers in Edinburgh and Bristol. This move will facilitate a successful conclusion to the trials in 2011 and partnered technology commercialization. Two further clinical trials will start in early 2011; with the University of Liverpool on hospital superbug Clostridium difficile and with the Institute of Food Research for reduction of cardiovascular inflammation using novel plant-derived extracts.